Dupixent gets extended use for certain atopic dermatitis in adolescents

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has OKd extension for Dupixent, following this week’s USFDA’s approval for chronic rhinosinusitis with nasal polyposis (CRSwNP), enabling its approval in the European Union (EU) to also include adolescents 12 to 17 years of age with moderate-to-severe AD who are candidates for systemic therapy.

If approved, Dupixent would be the first biologic medicine available in the EU to treat these patients, it was noted in the press release. A final decision on the Dupixent application by the European Commission (EC) is expected in the coming months.

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a central role in type 2 inflammation. Data from Dupixent clinical trials have shown that inhibiting IL-4 and IL-13 helps address the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).